MBX Biosciences is a clinical-stage biopharmaceutical company that specializes in developing therapies to treat rare endocrine diseases and metabolic disorders.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/05/2024 | Series C | $63.5MM | $xx.xx | $31.67B | Deep Track Capital, Driehaus Capital Management, Frazier Life Sciences, Orbimed, T. Rowe Price Associates, Wellington Management | |
Price per Share
$xx.xx
Shares Outstanding
61,650,480
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Deep Track Capital, Driehaus Capital Management, Frazier Life Sciences, Orbimed, T. Rowe Price Associates, Wellington Management
|
||||||
11/14/2022 | Series B | $116.32MM | $xx.xx | $23.51B | Frazier Life Sciences, Nea, Norwest Venture Partners, Orbimed, Ra Capital Management, Wellington Management | |
Price per Share
$xx.xx
Shares Outstanding
129,240,032
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Frazier Life Sciences, Nea, Norwest Venture Partners, Orbimed, Ra Capital Management, Wellington Management
|
||||||
07/27/2020 | Series A | $36.82MM | $xx.xx | $6.14B | Biocrossroads, Frazier Healthcare Partners, IU Ventures, Nea, Orbimed, Twilight Venture Partners | |
Price per Share
$xx.xx
Shares Outstanding
53,598,587
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Biocrossroads, Frazier Healthcare Partners, IU Ventures, Nea, Orbimed, Twilight Venture Partners
|